MedTrace Logo

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

NCT00847860 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2015-05-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.

Conditions

Interventions

DRUG

Cilostazol

Cilostazol 100 mg bid for 12 months

DRUG

Aspirin

Aspirin 100 mg qd for 12 months

Sponsors & Collaborators

  • Zhejiang Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Huang Yining, MD PhD · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00847860 on ClinicalTrials.gov